# Targeted Immunotherapeutics In Dysbiotic Microbiomes - A Feasibility and Proof-of-Concept Study

> **NIH NIH R43** · EVIMERO, LLC · 2024 · $325,139

## Abstract

Project Summary Abstract Evimero NCATS P1 OPE Project
In the proposed work, we examine the feasibility of using target-specific polyclonal antibodies to intercept and
neutralize bioactive molecules in the gut microbiome milieu of humans with microbiome-driven inflammation
and loss of gut barrier function. Such molecules are the “bridge” between a taxonomically-disordered, or
dysbiotic microbiome, and the deleterious effects such microbiomes can have on human tissue. Upregulated
inflammatory signaling and loss of barrier integrity are two general, systems biology-level changes common to
multiple microbiome-associated disorders (MADS); by demonstrating our ability to neutralize these core
mediators of pathology, we will establish the feasibility, and prove the concept, of our approach.
The present project is enabled by work done by our collaborators at Oak Ridge National Laboratory, who
identified six protein classes as overabundant in metaproteomic surveys of fecal microbiomes of those with
inflammatory disorders of the gut (the “ORNL Protein Examples,” or “OPEs.”) Each of these proteins has
known impacts on colonic inflammation, loss of barrier function, or both, from prior studies. Here, we explore
neutralization of their impacts by polyclonal antibodies extracted from the eggs of laying hens immunized with
the target proteins of interest. Known as IgY (immunoglobulin Y), these antibodies have cost and performance
advantages superior to either monoclonal antibodies or mammalian polyclonals. In this study’s Specific Aims
we 1) Determine the impact of each OPE in a sophisticated human stem-cell-derived in vitro model of human
colonic epithelia and discover optimal exposure levels generating inflammatory or barrier-loss signals, and then
2) Determine the ability of each IgY antibody to neutralize those physiological impacts in the same model.
Information gleaned from this project will support our broad, long-term objectives, modulating microbiome
milieus to restore those protective pathways by mitigating damaging ones. Once the principle of selective,
polyclonal antibody-mediated functional modulation has been demonstrated here, we will be well-positioned to
obtain support for more ambitious – and costly – primary studies in multi-omics (metagenomics, metabolomics,
metaproteomics). These studies, assisted by artificial intelligence/machine learning, will generate detailed
microbiome molecular “maps,” revealing critical microbiome pathways (CMPs) that mediate final impact of
dysbiosis on the host. Those pathways will identify specific “nodes” at which a pathway can take a health-
promoting or health-impairing direction. Those nodes will represent specific proteins whose inhibition will tip
the prevailing balance in a favorable direction – and become the final, precise targets for our antibody-mediated
neutralization. We expect to combine multiple individually-targeted IgY antibodies into a new family of drugs
called critical microbiome pathway inhib...

## Key facts

- **NIH application ID:** 11007922
- **Project number:** 1R43TR005333-01
- **Recipient organization:** EVIMERO, LLC
- **Principal Investigator:** Julius G Goepp
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $325,139
- **Award type:** 1
- **Project period:** 2024-09-01 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11007922

## Citation

> US National Institutes of Health, RePORTER application 11007922, Targeted Immunotherapeutics In Dysbiotic Microbiomes - A Feasibility and Proof-of-Concept Study (1R43TR005333-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11007922. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*